Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia

Author(s): Tomas Palecek, Michal Fikrle, Eduard Nemecek, Lenka Bauerova, Petr Kuchynka, William E. Louch, Ivan Spicka, Romana Rysava.

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 4 , 2015

Become EABM
Become Reviewer

Abstract:

Friedreich’s ataxia (FA) is associated with progressive cardiac hypertrophy resulting from a genetic abnormality in the frataxin gene. Cardiac involvement is the most common cause of death (59%) in FA patients. Cardiac related death occurs at a significantly younger age than non-cardiac related death. Idebenone is a short-chain quinone analogue with a potent free-radical scavenger action. This drug has the potential to preserve and even improve mitochondrial function.Studies on Idebenone treatment showed rather conflicting results on FA cardiomyopathy. The present article reviews the clinical features of FA cardiomyopathy, imaging techniques used to diagnose, follow and monitor therapy which aimed to revert FA cardiomyopathy.

Keywords: Idebenone, Friedreich’s ataxia, Echocardiography.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 21
ISSUE: 4
Year: 2015
Page: [479 - 483]
Pages: 5
DOI: 10.2174/138161282104141204142917
Price: $58

Article Metrics

PDF: 30